AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Delcath Systems to Attend BTIG MedTech Conference in Utah
ByAinvest
Tuesday, Jan 27, 2026 8:08 am ET1min read
DCTH--
Delcath Systems, an interventional oncology company, will participate in the BTIG 13th Annual MedTech conference in Utah. The company's proprietary products, HEPZATO KIT and CHEMOSAT, are designed to treat primary and metastatic liver cancers. HEPZATO KIT is a combination drug and device product, while CHEMOSAT is a Class III medical device used in percutaneous hepatic perfusion procedures. The company's products aim to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc's editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet